EuroPMP members attended the 4th annual Nordic Peritoneal Oncology group meeting on March 9th, 2022 in Helsinki, Finland On Wednesday March 9th, the Nordic Peritoneal Oncology group was again able to organise a face-to-face meeting in Helsinki. Participants from peritoneal oncology centers in Denmark, Norway, Sweden and Finland participated, many of whom are also members of the EuroPMP COST Action, including Dr Anna Lepistö, who hosted the meeting. The Helsinki team had put together a varied and interesting scientific program, focusing on the clinical and research activities from the past two years at the participating centers, including activities relating to PMP. Of particular interest regarding the clinical activities, EuroPMP members…
-
-
Proceedings of the EuroPMP Pathology Workshop
Held the 10th December 2020 Chair: Professor Norman Carr Panel members: Drs Robert Bradley, Søren Krag, and Melissa Taggart. Presenters: Drs Peggy Dartigues, Marie-Louise (Loes) van Velthuysen, Wiebke Solass, Frédéric Bibeau, and Bipasha Chakrabarty.
-
Workshop on the Pathology of PMP – 10th December 2020
EuroPMP will present a workshop on the pathology of PMP on 10th December 2020. The proceedings of the workshop will be available to view online following the workshop. The workshop is being presented by Dr Norman Carr and will run from 17:00-18:45 GMT (18:00-19:45 CET). Please check your email for more information. Before the meeting, you may wish to read more about the pathology of PMP to get acquainted with the terminology and histology of the disease. Dr Carr has prepared a short primer on the topic, which you can access at this link. The programme for the workshop can be accessed here. To view a recording of the workshop,…
-
Incidence and Prevalence in Europe
EuroPMP member researchers from Norway and the United Kingdom have recently published a paper giving a sound scientific footing for the incidence and prevalence of PMP in Europe. The research suggests that the previous incidence estimate of 1-2 persons per million is too low, with a more realistic figure being around 3.2 persons per million. The prevalence was estimated to be around 22 persons per million in Europe, meaning 11,726 people living with active disease in 2018. The incidence and prevalence paper can be read here.
-
The Effects of COVID-19 on PMP Services Around Europe
Around the world, the COVID-19 epidemic has been hitting our health care systems very hard. Intensive care units have been inundated with patients requiring careful, around-the-clock care. Physicians have been transferred from their normal duties to hastily set up critical care wards within their districts to try to treat the vast numbers of affected patients. Nurses have been sent out to test patients in temporary drive-up clinics, and biologists and lab workers have had their normal duties re-directed to include testing the enormous numbers of patient samples incoming daily from worried patients. We have heard much about the effects on primary care physicians and clinical specialists, but we have not…
-
New STSM to Oslo
Yaroslaw Sautkin, a EuroPMP member from Germany, has completed a Short-Term Scientific Mission to Professor Kjersti Flatmark’s Translational Cancer Therapy lab at Oslo University Hospital’s Institute for Cancer Research. While on his STSM, Yaroslaw learned more about the use of experimental animal models for pseudomyxoma peritonei (PMP) in order to further the work that his own institution, the University of Tübingen, is undertaking into the use of PIPAC with mucolytic substances. Yaroslaw’s visit allowed members of both teams to meet and share knowledge, leading to stronger synergies between their researchers. Both groups are now looking forward to working on research projects together in the future. STSMs are offered several times…